Biogen Makes $200M Alzheimer's Drug Deal with Proteostasis

Massachusetts-based Proteostasis has entered into a worldwide collaboration with Biogen Idec to develop drugs that could treat certain neurodegenerative disorders, such as Alzheimer’s and Parkinson’s, by blocking an enzyme known as Usp14

According to Proteostasis, it will receive an initial upfront payment from Biogen (a leader in the multiple sclerosis field), along with an equity investment, and is eligible for research funding support and future development and commercial milestones that could result in total payments of up to $200 million, as well as tiered royalties.

Read the Proteostasis press release

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments